Last $21.00 USD
Change Today -0.09 / -0.43%
Volume 6.8K
HLUYY On Other Exchanges
Symbol
Exchange
Copenhagen
Stuttgart
OTC US
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s-spn adr (HLUYY) Snapshot

Open
$21.00
Previous Close
$21.09
Day High
$21.11
Day Low
$20.99
52 Week High
03/24/14 - $32.00
52 Week Low
09/5/13 - $20.11
Market Cap
4.1B
Average Volume 10 Days
6.9K
EPS TTM
--
Shares Outstanding
196.4M
EX-Date
04/2/14
P/E TM
--
Dividend
$0.51
Dividend Yield
2.44%
Current Stock Chart for H LUNDBECK A/S-SPN ADR (HLUYY)

Related News

No related news articles were found.

h lundbeck a/s-spn adr (HLUYY) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. H. Lundbeck A/S has strategic research collaboration with Ossianix, Inc. The company was founded in 1915 and is based in Valby, Denmark.

Founded in 1915

h lundbeck a/s-spn adr (HLUYY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s-spn adr (HLUYY) Key Developments

H. Lundbeck A/S, Q2 2014 Earnings Call, Aug 07, 2014

H. Lundbeck A/S, Q2 2014 Earnings Call, Aug 07, 2014

H. Lundbeck A/S Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

H. Lundbeck A/S announced unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of DKK 3,448 million against DKK 3,536 million a year ago. Profit from operations was DKK 274 million against loss from operations of DKK 506 million a year ago. Profit before tax was DKK 240 million against loss before tax of DKK 550 million a year ago. Profit for the period was DKK 144 million or DKK 0.73 per diluted share against loss of DKK 502 million or DKK 2.56 per diluted share a year ago. Cash flows from operating activities were DKK 459 million against DKK 1,346 million a year ago. Investments in intangible assets and property, plant and equipment was DKK 1,209 million against DKK 725 million a year ago. Return on equity was 1.1% against negative return on equity of 3.7% a year ago. Operating profit before depreciation and amortization (EBITDA) was DKK 540 million against DKK 10 million a year ago. Core profit from operations (core EBIT) was DKK 439 million against DKK 566 million a year ago. Cash flow per share was DKK 2.33 against DKK 6.86 a year ago. For the six months, the company reported revenue of DKK 7,035 million against DKK 8,112 million a year ago. Profit from operations was DKK 843 million against DKK 1,020 million a year ago. Profit before tax was DKK 792 million against DKK 974 million a year ago. Profit for the period was DKK 475 million against DKK 565 million a year ago. Diluted earrings per share were DKK 2.42 against DKK 2.88 a year ago. Cash flows from operating activities were DKK 308 million against DKK 1,973 million a year ago. Investments in intangible assets and property, plant and equipment was DKK 1,277 million against DKK 809 million a year ago. Return on equity was 3.5% against 4.2% a year ago. Cash flow per share was DKK 1.57 against DKK 10.06 a year ago. Operating profit before depreciation and amortization (EBITDA) was DKK 1,364 million against DKK 1,776 million a year ago. Core profit from operations (core EBIT) was DKK 1,168 million against DKK 1,487 million a year ago. For the fiscal year 2014, the company expects constant currency revenue to be around DKK 13.5 billion. The company expects core profit from operations (core EBIT) in constant currency to be in the range DKK 0.9-1.4 billion for 2014. Expected reported profit from operations (EBIT) in constant currency is unchanged at DKK 0.0-0.5 billion for 2014 as a result of the acquisition of Chelsea Therapeutics, increased generic erosion, continued investment in an unprecedented number of product launches and significant costs related to the continued progress of key late-stage clinical development projects. For 2015, the company announced that it is expects structural tax rate, due to the more heavy earnings from U.S, will change to between 28 to 30% points compared to revenue.

Otsuka and Lundbeck Submit New Drug Application for Brexpiprazole for Treatment of Schizophrenia and as Adjunctive Therapy for Treatment of Major Depression

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for brexpiprazole for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder (MDD). The clinical development program included data from more than 6,500 participants of whom more than 5,300 received brexpiprazole. Following the submission the FDA will determine if the NDA is sufficiently complete to allow for a substantive review of the data; a decision from the FDA on initiation of the substantive review is expected in September 2014. Brexpiprazole is a novel investigational psychotropic compound discovered by Otsuka and under co-development with Lundbeck. Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUYY:US $21.00 USD -0.09

HLUYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HLUYY.
View Industry Companies
 

Industry Analysis

HLUYY

Industry Average

Valuation HLUYY Industry Range
No financial data is available for HLUYY.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S-SPN ADR, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.